S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.21 (+3.17%)
AAPL   145.96 (+2.46%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.61 (+3.01%)
AMZN   121.09 (+4.50%)
TSLA   249.08 (+2.76%)
NVDA   131.72 (+5.27%)
NIO   16.71 (+7.88%)
BABA   84.21 (+4.67%)
AMD   67.83 (+2.60%)
T   16.09 (+1.19%)
MU   53.98 (+4.37%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.76 (+12.79%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.21 (+3.17%)
AAPL   145.96 (+2.46%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.61 (+3.01%)
AMZN   121.09 (+4.50%)
TSLA   249.08 (+2.76%)
NVDA   131.72 (+5.27%)
NIO   16.71 (+7.88%)
BABA   84.21 (+4.67%)
AMD   67.83 (+2.60%)
T   16.09 (+1.19%)
MU   53.98 (+4.37%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.76 (+12.79%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.21 (+3.17%)
AAPL   145.96 (+2.46%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.61 (+3.01%)
AMZN   121.09 (+4.50%)
TSLA   249.08 (+2.76%)
NVDA   131.72 (+5.27%)
NIO   16.71 (+7.88%)
BABA   84.21 (+4.67%)
AMD   67.83 (+2.60%)
T   16.09 (+1.19%)
MU   53.98 (+4.37%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.76 (+12.79%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.21 (+3.17%)
AAPL   145.96 (+2.46%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.61 (+3.01%)
AMZN   121.09 (+4.50%)
TSLA   249.08 (+2.76%)
NVDA   131.72 (+5.27%)
NIO   16.71 (+7.88%)
BABA   84.21 (+4.67%)
AMD   67.83 (+2.60%)
T   16.09 (+1.19%)
MU   53.98 (+4.37%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.76 (+12.79%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
NASDAQ:TXMD

TherapeuticsMD - TXMD Stock Forecast, Price & News

$6.94
+0.80 (+13.03%)
(As of 10/4/2022 03:59 PM ET)
Add
Compare
Today's Range
$6.38
$6.94
50-Day Range
$6.14
$10.40
52-Week Range
$1.99
$40.90
Volume
620 shs
Average Volume
98,514 shs
Market Capitalization
$65.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$125.00

TherapeuticsMD MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,701.2% Upside
$125.00 Price Target
Short Interest
Healthy
4.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.82mentions of TherapeuticsMD in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$22.47 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($11.07) to ($2.04) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

522nd out of 1,087 stocks

Pharmaceutical Preparations Industry

242nd out of 546 stocks

TXMD stock logo

About TherapeuticsMD (NASDAQ:TXMD) Stock

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Receive TXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.

TXMD Stock News Headlines

TherapeuticsMD Announces $7 Million Private Placement
TherapeuticsMD, Inc. (NASDAQ: TXMD)
TherapeuticsMD: Q2 Earnings Snapshot - Greenwich Time
See More Headlines
Receive TXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.

TXMD Company Calendar

Last Earnings
8/15/2022
Today
10/04/2022
Next Earnings (Estimated)
11/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TXMD
Previous Symbol
NYSEMKT:TXMD
Employees
416
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$125.00
High Stock Price Forecast
$125.00
Low Stock Price Forecast
$125.00
Forecasted Upside/Downside
+1,701.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-172,410,000.00
Pretax Margin
-28.89%

Debt

Sales & Book Value

Annual Sales
$86.95 million
Book Value
($11.05) per share

Miscellaneous

Free Float
8,596,000
Market Cap
$65.37 million
Optionable
Optionable
Beta
1.54

Key Executives

  • Governor Thomas G. Thompson (Age 80)
    Exec. Chairman
    Comp: $100k
  • Mr. Hugh O'Dowd M.B.A. (Age 57)
    Pres & Director
    Comp: $1.19M
  • Mr. Robert G. FinizioMr. Robert G. Finizio (Age 51)
    Co-Founder
    Comp: $2.53M
  • Mr. Marlan D. Walker J.D.Mr. Marlan D. Walker J.D. (Age 47)
    Gen. Counsel & Secretay
    Comp: $506.21k
  • Mr. Mark A. Glickman (Age 56)
    Interim Co-CEO & Co-Principal Exec. Officer
  • Dr. Brian A. Bernick F.A.C.O.G. (Age 54)
    M.D., Co-Founder and Chief Scientific & Medical Officer
  • Mr. Michael C. Donegan (Age 54)
    Interim CFO, Chief Accounting Officer and Principal Financial & Accounting Officer
  • Ms. Daniella Silva (Age 36)
    Chief Compliance Officer
  • Mr. Benjamin Foulk (Age 52)
    VP of HR
  • Mr. Mitchell L. Krassan (Age 56)
    Exec. VP and Chief Strategy & Performance Officer













TXMD Stock - Frequently Asked Questions

Should I buy or sell TherapeuticsMD stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares.
View TXMD analyst ratings
or view top-rated stocks.

What is TherapeuticsMD's stock price forecast for 2022?

2 equities research analysts have issued 12-month price objectives for TherapeuticsMD's shares. Their TXMD share price forecasts range from $125.00 to $125.00. On average, they expect the company's stock price to reach $125.00 in the next twelve months. This suggests a possible upside of 1,701.2% from the stock's current price.
View analysts price targets for TXMD
or view top-rated stocks among Wall Street analysts.

How have TXMD shares performed in 2022?

TherapeuticsMD's stock was trading at $17.7750 on January 1st, 2022. Since then, TXMD shares have decreased by 61.0% and is now trading at $6.94.
View the best growth stocks for 2022 here
.

When is TherapeuticsMD's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our TXMD earnings forecast
.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) released its quarterly earnings results on Monday, August, 15th. The company reported ($2.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.04) by $0.89. The firm had revenue of $28.56 million for the quarter, compared to analyst estimates of $23.20 million. During the same period in the prior year, the business earned ($5.50) earnings per share.

When did TherapeuticsMD's stock split?

TherapeuticsMD shares reverse split on the morning of Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

How do I buy shares of TherapeuticsMD?

Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $6.94.

How much money does TherapeuticsMD make?

TherapeuticsMD (NASDAQ:TXMD) has a market capitalization of $65.37 million and generates $86.95 million in revenue each year. The company earns $-172,410,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis.

How many employees does TherapeuticsMD have?

The company employs 416 workers across the globe.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The official website for the company is www.therapeuticsmd.com. The company can be reached via phone at (561) 961-1900, via email at shareholder@broadridge.com, or via fax at 561-431-3389.

This page (NASDAQ:TXMD) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.